Protein aggregation and its impact on product quality

Current Opinion in Biotechnology

Volumn 30, Issue , 2014, Pages 211-217

  Roberts, Christopher J ^a  

^a UNIVERSITY OF DELAWARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGGREGATES; CHAINS; DRUG PRODUCTS; MONOCLONAL ANTIBODIES; QUALITY CONTROL;

AGGREGATE FORMATION; DRUG PIPELINE; HEAVY AND LIGHT CHAINS; PHARMACEUTICAL INDUSTRY; PHARMACEUTICAL PRODUCTS; PROTEIN AGGREGATION; PROTEIN CHAINS; PROTEIN PHARMACEUTICALS;

PROTEINS;

AMINO ACID SEQUENCE; CONCENTRATION RESPONSE; DRUG INDUSTRY; IONIC STRENGTH; MOLECULAR INTERACTION; PH; PHYSICAL CHEMISTRY; PRESSURE GRADIENT; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN FOLDING; PROTEIN STABILITY; QUALITY CONTROL; REVIEW; SOLUBILITY; TEMPERATURE SENSITIVITY; CRYSTAL STRUCTURE; DRUG ADMINISTRATION ROUTE; DRUG QUALITY; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; NONHUMAN; PHASE SEPARATION; PROTEIN DEGRADATION; PROTEIN SECRETION; PROTEIN UNFOLDING; METABOLISM; PHARMACEUTICS; PROTEIN ENGINEERING;

AMPHOPHILE; DIMER; INSULIN; MONOCLONAL ANTIBODY; MONOMER; OLIGOMER; ZINC ION; PROTEIN AGGREGATE; RECOMBINANT PROTEIN;

BIOPHARMACEUTICS; PROTEIN AGGREGATES; PROTEIN ENGINEERING; PROTEIN FOLDING; QUALITY CONTROL; RECOMBINANT PROTEINS;

EID: 84907260610     PISSN: 09581669     EISSN: 18790429     Source Type: Journal    
DOI: 10.1016/j.copbio.2014.08.001     Document Type: Review

References (65)

1. Rob Aggarwal S. What's fueling the biotech engine - 2012 to 2013. Nat Biotechnol 2014, 32:32-39.
2. Smart A.L., Gaisford S., Basit A.W. Oral peptide and protein delivery: intestinal obstacles and commercial prospects. Expert Opin Drug Deliv 2014, 10.1517/17425247.2014.917077.
3. Li X., Yu M., Fan W., Gan Y., Hovgaard L., Yang M. Orally active-targeted drug delivery systems for proteins and peptides. Expert Opin Drug Deliv 2014, 10.1517/17425247.2014.924500.
4. Anselmo A.C., Mitragotri S. An overview of clinical and commercial impact of drug delivery systems. J Control Release: Off J Control Release Soc 2014, 10.1016/j.jconrel.2014.03.053.
5. Wang W. Protein aggregation and its inhibition in biopharmaceutics. Int J Pharm 2005, 289:1-30.
6. Creighton T.E. Protein Folding 1992, W.H. Freeman and Co.
7. Fink A.L. Protein aggregation: folding aggregates, inclusion bodies and amyloid. Fold Des 1998, 3:R9-R23.
8. Dumetz A.C., Chockla A.M., Kaler E.W., Lenhoff A.M. Comparative effects of salt, organic, and polymer precipitants on protein phase behavior and implications for vapor diffusion. Cryst Growth Des 2009, 9:682-691.
9. Kroetsch A.M., Sahin E., Wang H.Y., Krizman S., Roberts C.J. Relating particle formation to salt- and pH-dependent phase separation of non-native aggregates of alpha-chymotrypsinogen A. J Pharm Sci 2012, 101:3651-3660.
10. Chothia C., Janin J. Principles of protein-protein recognition. Nature 1975, 256:705-708.
11. Brange J., Andersen L., Laursen E.D., Meyn G., Rasmussen E. Toward understanding insulin fibrillation. J Pharm Sci 1997, 86:517-525.
12. Weiss W.F., Young T.M., Roberts C.J. Principles, approaches, and challenges for predicting protein aggregation rates and shelf life. J Pharm Sci 2009, 98:1246-1277.
13. Fernandez C., Minton A.P. Static light scattering from concentrated protein solutions. II: Experimental test of theory for protein mixtures and weakly self-associating proteins. Biophys J 2009, 96:1992-1998.
14. Connolly B.D., Petry C., Yadav S., Demeule B., Ciaccio N., Moore J.M.R., Shire S.J., Gokarn Y.R. Weak interactions govern the viscosity of concentrated antibody solutions: high-throughput analysis using the diffusion interaction parameter. Biophys J 2012, 103:69-78.
15. Schmit J.D., He F., Mishra S., Ketchem R.R., Woods C.E., Kerwin B.A. Entanglement model of antibody viscosity. J Phys Chem B 2014, 118:5044-5049.
16. Yearley E.J., Zarraga I.E., Shire S.J., Scherer T.M., Gokarn Y., Wagner N.J., Liu Y. Small-angle neutron scattering characterization of monoclonal antibody conformations and interactions at high concentrations. Biophys J 2013, 105:720-731.
17. Godfrin P.D., Castañeda-Priego R., Liu Y., Wagner N.J. Intermediate range order and structure in colloidal dispersions with competing interactions. J Chem Phys 2013, 139:154904.
18. Falus P., Porcar L., Fratini E., Chen W.-R., Faraone A., Hong K., Baglioni P., Liu Y. Distinguishing the monomer to cluster phase transition in concentrated lysozyme solutions by studying the temperature dependence of the short-time dynamics. J Phys Condens Matter: Inst Phys J 2012, 24:064114.
19. Stradner A., Cardinaux F., Schurtenberger P. A small-angle scattering study on equilibrium clusters in lysozyme solutions. J Phys Chem B 2006, 110:21222-21231.
20. Piazza R. Protein interactions and association: an open challenge for colloid science. Curr Opin Colloid Interface Sci 2004, 8:515-522.
21. Johnston K.P., Maynard J.A., Truskett T.M., Borwankar A.U., Miller M.A., Wilson B.K., Dinin A.K., Khan T.A., Kaczorowski K.J. Concentrated dispersions of equilibrium protein nanoclusters that reversibly dissociate into active monomers. ACS Nano 2012, 6:1357-1369.
22. McPherson A., Gavira J.A. Introduction to protein crystallization. Acta Crystallogr Sect F: Struct Biol Commun 2014, 70:2-20.
23. Smejkal B., Agrawal N.J., Helk B., Schulz H., Giffard M., Mechelke M., Ortner F., Heckmeier P., Trout B.L., Hekmat D. Fast and scalable purification of a therapeutic full-length antibody based on process crystallization. Biotechnol Bioeng 2013, 110:2452-2461.
24. Lewus R.A., Darcy P.A., Lenhoff A.M., Sandler S.I. Interactions and phase behavior of a monoclonal antibody. Biotechnol Prog 2011, 27:280-289.
25. Mason B.D., Zhang-van Enk J., Zhang L., Remmele R.L., Zhang J. Liquid-liquid phase separation of a monoclonal antibody and nonmonotonic influence of hofmeister anions. Biophys J 2010, 99:3792-3800.
26. Sukumar M., Doyle B.L., Combs J.L., Pekar A.H. Opalescent appearance of an IgG1 antibody at high concentrations and its relationship to noncovalent association. Pharm Res 2004, 21:1087-1093.
27. Salinas B.A., Sathish H.A., Bishop S.M., Harn N., Carpenter J.F., Randolph T.W. Understanding and modulating opalescence and viscosity in a monoclonal antibody formulation. J Pharm Sci 2010, 99:82-93.
28. Brummitt R.K., Andrews J.M., Jordan J.L., Fernandez E.J., Roberts C.J. Thermodynamics of amyloid dissociation provide insights into aggregate stability regimes. Biophys Chem 2012, 168-169:10-18.
29. Maurer R.W., Hunter A.K., Robinson A.S., Roberts C.J. Aggregates of α-chymotrypsinogen anneal to access more stable states. Biotechnol Bioeng 2014, 111:782-791.
30. Lefebvre B.G., Robinson A.S. Pressure treatment of tailspike aggregates rapidly produces on-pathway folding intermediates. Biotechnol Bioeng 2003, 82:595-604.
31. Foguel D., Robinson C.R., Caetano D.S., Silva J.L., Robinson A.S. Hydrostatic pressure rescues native protein from aggregates. Biotechnol Bioeng 1999, 63:552-558.
32. Seefeldt M.B., Ouyang J., Froland W.A., Carpenter J.F., Randolph T.W. High-pressure refolding of bikunin: efficacy and thermodynamics. Protein Sci Publ Protein Soc 2004, 13:2639-2650.
33. Li Y., Ogunnaike B.A., Roberts C.J. Multi-variate approach to global protein aggregation behavior and kinetics: effects of pH, NaCl, and temperature for α-chymotrypsinogen A. J Pharm Sci 2010, 99:645-662.
34. Brummitt R.K., Nesta D.P., Chang L., Kroetsch A.M., Roberts C.J. Nonnative aggregation of an IgG1 antibody in acidic conditions. Part 2: Nucleation and growth kinetics with competing growth mechanisms. J Pharm Sci 2011, 100:2104-2119.
35. Kim N., Remmele R.L., Liu D., Razinkov V.I., Fernandez E.J., Roberts C.J. Aggregation of anti-streptavidin immunoglobulin gamma-1 involves Fab unfolding and competing growth pathways mediated by pH and salt concentration. Biophys Chem 2013, 172:26-36.
36. Sahin E., Weiss W.F., Kroetsch A.M., King K.R., Kessler R.K., Das T.K., Roberts C.J. Aggregation and pH-temperature phase behavior for aggregates of an IgG2 antibody. J Pharm Sci 2012, 10.1002/jps.23056.
37. Roberts C.J. Non-native protein aggregation kinetics. Biotechnol Bioeng 2007, 98:927-938.
38. Banks D.D., Latypov R.F., Ketchem R.R., Woodard J., Scavezze J.L., Siska C.C., Razinkov V.I. Native-state solubility and transfer free energy as predictive tools for selecting excipients to include in protein formulation development studies. J Pharm Sci 2012, 101:2720-2732.
39. Roberts C.J. Therapeutic protein aggregation: mechanisms, design, and control. Trends Biotechnol 2014, 32:372-380.
40. Weiss W.F., Hodgdon I.V., Kaler T.K., Lenhoff E.W., Roberts CJ: A.M. Nonnative protein polymers: structure, morphology, and relation to nucleation and growth. Biophys J 2007, 93:4392-4403.
41. Pathak J.A., Sologuren R.R., Narwal R. Do clustering monoclonal antibody solutions really have a concentration dependence of viscosity?. Biophys J 2013, 104:913-923.
42. Mahler H.-C., Fischer S., Randolph T.W., Carpenter J.F. Protein Aggregation and Particle Formation: Effects of Formulation, Interfaces, and Drug Product Manufacturing Operations 2010, 301-331. John Wiley & Sons, Inc.
43. Wiesbauer J., Prassl R., Nidetzky B. Renewal of the air-water interface as a critical system parameter of protein stability: aggregation of the human growth hormone and its prevention by surface-active compounds. Langmuir ACS J Surf Colloids 2013, 29:15240-15250.
44. Bee J.S., Schwartz D.K., Trabelsi S., Freund E., Stevenson J.L., Carpenter J.F., Randolph T.W. Production of particles of therapeutic proteins at the air-water interface during compression/dilation cycles. Soft Matter 2012, 8:10329-10335.
45. Biddlecombe J.G., Smith G., Uddin S., Mulot S., Spencer D., Gee C., Fish B.C., Bracewell D.G. Factors influencing antibody stability at solid-liquid interfaces in a high shear environment. Biotechnol Prog 2009, 25:1499-1507.
46. Bee J.S., Davis M., Freund E., Carpenter J.F., Randolph T.W. Aggregation of a monoclonal antibody induced by adsorption to stainless steel. Biotechnol Bioeng 2009, 105:121-129.
47. Gualandi-Signorini A.M., Giorgi G. Insulin formulations - a review. Eur Rev Med Pharmacol Sci 2001, 5:73-83.
48. Jiskoot W., Randolph T.W., Volkin D.B., Middaugh C.R., Schöneich C., Winter G., Friess W., Crommelin D.J.A., Carpenter J.F. Protein instability and immunogenicity: roadblocks to clinical application of injectable protein delivery systems for sustained release. J Pharm Sci 2012, 101:946-954.
49. Macdougall I.C. Antibody-mediated pure red cell aplasia (PRCA): epidemiology, immunogenicity and risks. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc: Eur Ren Assoc 2005, 20(Suppl. 4). iv9-iv15.
50. Lin H.-K., Chase S.F., Laue T.M., Jen-Jacobson L., Trakselis M.A. Differential temperature-dependent multimeric assemblies of replication and repair polymerases on DNA increase processivity. Biochemistry (Mosc) 2012, 51:7367-7382.
51. Saluja A., Sadineni V., Mungikar A., Nashine V., Kroetsch A., Dahlheim C., Rao V.M. Significance of unfolding thermodynamics for predicting aggregation kinetics: a case study on high concentration solutions of a multi-domain protein. Pharm Res 2014, 10.1007/s11095-013-1263-5.
52. Wang W., Roberts C.J. Non-Arrhenius protein aggregation. AAPS J 2013, 15:840-851.
53. Kayser V., Chennamsetty N., Voynov V., Helk B., Forrer K., Trout B.L. Evaluation of a non-Arrhenius model for therapeutic monoclonal antibody aggregation. J Pharm Sci 2011, 100:2526-2542.
54. Roche J., Caro J.A., Norberto D.R., Barthe P., Roumestand C., Schlessman J.L., Garcia A.E., Garcia-Moreno E.B., Royer C.A. Cavities determine the pressure unfolding of proteins. Proc Natl Acad Sci U S A 2012, 109:6945-6950.
55. Dumetz A.C., Snellinger-O'Brien A.M., Kaler E.W., Lenhoff A.M. Patterns of protein-protein interactions in salt solutions and implications for protein crystallization. Protein Sci 2007, 16:1867-1877.
56. Broering J.M., Bommarius A.S. Evaluation of Hofmeister effects on the kinetic stability of proteins. J Phys Chem B 2005, 109:20612-20619.
57. Auton M., Rösgen J., Sinev M., Holthauzen L.M.F., Bolen D.W. Osmolyte effects on protein stability and solubility: a balancing act between backbone and side-chains. Biophys Chem 2011, 159:90-99.
58. Webb J.N., Webb S.D., Cleland J.L., Carpenter J.F., Randolph T.W. Partial molar volume, surface area, and hydration changes for equilibrium unfolding and formation of aggregation transition state: high-pressure and cosolute studies on recombinant human IFN-γ. Proc Natl Acad Sci U S A 2001, 98:7259-7264.
59. Berger B.W., Gendron C.M., Lenhoff A.M., Kaler E.W. Effects of additives on surfactant phase behavior relevant to bacteriorhodopsin crystallization. Protein Sci 2006, 15:2682-2696.
60. O'Malley M.A., Helgeson M.E., Wagner N.J., Robinson A.S. The morphology and composition of cholesterol-rich micellar nanostructures determine transmembrane protein (GPCR) activity. Biophys J 2011, 100:L11-L13.
61. Roberts C.J., Das T.K., Sahin E. Predicting solution aggregation rates for therapeutic proteins: approaches and challenges. Int J Pharm 2011, 418:318-333.
62. Wakankar A.A., Borchardt R.T. Formulation considerations for proteins susceptible to asparagine deamidation and aspartate isomerization. J Pharm Sci 2006, 95:2321-2336.
63. Torosantucci R., Schöneich C., Jiskoot W. Oxidation of therapeutic proteins and peptides: structural and biological consequences. Pharm Res 2014, 31:541-553.
64. Liu D., Ren D., Huang H., Dankberg J., Rosenfeld R., Cocco M.J., Li L., Brems D.N., Remmele R.L. Structure and stability changes of human IgG1 Fc as a consequence of methionine oxidation. Biochemistry (Mosc) 2008, 47:5088-5100.
65. Roberts C.J., Nesta D.P., Kim N. Effects of temperature and osmolytes on competing degradation routes for an IgG1 antibody. J Pharm Sci 2013, 102:3556-3566.